Study design: A systematic review of clinical and preclinical literature. Objective: To critically evaluate the evidence supporting a role for vasopressor support in the management of acute spinal cord injury and to provide updated recommendations regarding the appropriate clinical application of this therapeutic modality. Background: Only few clinical studies exist examining the role of arterial pressure and vasopressors in the context of spinal cord trauma. Methods: Medical literature was searched from the earlier available date to July 2009 and 32 articles (animal and human literature) answering the following four questions were studied: what patient groups benefit from vasopressor support, which is the optimal hypertensive drug regimen, which is the optimal duration of the treatment and which is the optimal arterial blood pressure. Outcome measures used were the incidence of patients needing vasopressors, the increase of arterial blood pressure and neurologic improvement. Results: Patients with complete cervical cord injuries required vasopressors more frequently than either incomplete injuries or thoracic/lumbar cord injuries (Po0.001). There was no statististical difference in neurologic improvement between patients on vasopressor support with a mean arterial pressure (MAP) of less than 85 mm Hg and those with MAP less than 90 mm Hg. Duration of treatment is often recommended between 5 and 7 days although this is not supported by high-level evidence and no single vasopressor appeared superior over the variety used in clinical treatment. Conclusion: There is currently no gold standard on vasopressor support. Based on non-randomized human studies, complete cervical cord injuries require vasopressors more frequently than other spinal cord injuries.
Introduction
The incidence of cardiovascular abnormalities following acute spinal cord injuries (ASCIs) is very common, particularly after cervical injuries. [1] [2] [3] Many patients exhibit hypotension and bradycardia due a sudden loss of sympathetic outflow and relative hypovolemia. This combination, referred to as 'neurogenic shock', is common in patients with acute cervical tetraplegia or high thoracic paraplegia. With impaired spinal cord autoregulation, this neurogenic shock can contribute to hypoperfusion of the spinal cord and further ischemic insult. In a study conducted by Lehmann et al. 1 100% of the patients that had a severe cervical injury suffered from persistent bradycardia and 68% of the patients suffered from hypotension. Given the paucity of effective interventions for acute human SCI, it is important that all possible clinical measures be taken to minimize secondary damage and potentially improve neurologic outcome. In traumatic brain injury, restoring normal blood pressure has proven to be beneficial for neurologic recovery, and aggressive vasopressor support with fastidious monitoring of systemic and intracranial pressure is standard of care for these patients in most neurotrauma institutions. 4 Comparatively less is known about traumatic spinal cord injury (SCI), however. In two studies, aggressively providing hemodynamic support to maintain adequate perfusion and blood pressure was shown to improve the mortality rates and neurological outcome of patients with ASCI. 5, 6 Guidelines have recently been published by the Spinal Cord Medicine Consortium that provide direction for clinicians in their hemodynamic management of patients with ASCI. 7 Here, we performed a systematic review of the literature on the topic of hemodynamic support for ASCI, with the goals of characterizing the clinical phenomenon of neurogenic shock, evaluating appropriate vasopressor agents, determining the optimal duration of treatment and identifying the hemodynamic parameters that warrant commencement of vasopressors. 14 Patients with severe cervical cord injuries are more prone to hemodynamic and cardiac abnormalities within the first 1-2 weeks after injury.
Materials and methods
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Lehmann et al. 1 found hypotension in 68% of the studied patients with SCI with complete cervical cord injury and no hypotension in either incomplete cervical or thoracolumbar cord injuries. In a retrospective study of patients with SCIs receiving appropriate medical and surgical treatment, motor complete patients initially showed a neurologic motor recovery rate of up to 15% whereas motor incomplete patients showed a motor recovery rate of 80% on average. 15 As to the level of paralysis (cervical vs thoracic), only four studies (including Lehmann et al.) evaluated the institution of vasopressor support based on level of injury. Patients with cervical cord injuries required vasopressor support more frequently than patients with thoracolumbar injuries (Po0.001; Table 3 ).
This review confirms that the need for vasopressors is more pronounced in cervical cord injuries with complete neurologic deficit. This does not mean that vasopressors are unnecessary in cases of incomplete injuries or thoracic/ lumbar cord injuries, but rather, that hypotension is less commonly experienced in these settings.
What is the best hypertensive drug regimen depending on its actions? In a study by Levi et al. 5 on 50 patients with cervical ASCI, dobutamine (5-15 mg kg À1 per min) and/or dopamine Five studies using different vasopressor agents were reviewed ( Table 4 ). All of them were successful in improving blood pressure above the targeted critical value. Owing to the heterogeneity of the studies, no statistical analysis could be performed to determine which, if any, of the vasopressor agents are better.
What is the optimal duration of treatment? There were four studies reporting the optimal duration of vasopressor support (Table 5 ). Treatment ranged from 5 to 7 days on average. Most of the reported findings were not specific for their effect on the cardiovascular system or neurologic recovery. Therefore, optimal treatment duration could not be determined.
What is the MAP below which one should commence vasopressor support? Four studies (Table 2 ) evaluated neurologic improvement following pressure support initiation for MAPo85 or o90 as criterion for initiating therapy. There was no significant difference (P40.05) in terms of neurologic improvement between the initiation of pressures for an MAPo85 or o90 as a criterion for initiating therapy.
Discussion
Hypotension in acute spinal cord injured patients leads to decreased cord perfusion and the potential for further secondary ischemic cord injury. 16 Before initiating any vasopressor agent, proper fluid replacement is required to enhance the action of the vasopressors. 17 The target pulmonary capillary wedge pressure is approximately 18 mm Hg with a systolic arterial pressure between 80 and 100 mm Hg. 18, 19 Volume resuscitation is undertaken first by crystalloids and then by colloids (that is, dextran, fresh frozen plasma or red blood cell units when hemoglobin is low). Other causes of hemodynamic instability (that is, bleeding, tension pneumothorax, myocardial infraction, cardiac tamponade, sepsis) should be excluded before attributing hemodynamic instability to neurogenic shock. Spinal cord blood flow has been shown to be adversely affected following traumatic SCI and an increase in blood pressure leads to significant improvement in axonal function both in the motor and somatosensory tracts of the cord.
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The sympathetic supply to the heart originates in T1-T4 cord level. Injuries at or above this level lead to decreased myocardial contractility and heart rate. In addition, irrespective of the level of cord injury, supraspinal sympathetic drive to the peripheral vessels is interrupted, and the pooling of blood within the peripheral circulation leads to hypotension. 22 In Table 6 , the most widely used vasopressors are listed. Vasopressors that are a-receptor agonists result in peripheral vasoconstriction and elevation of blood pressure. b-Receptors agonists are responsible for increased cardiac contractility and heart rate. According to the recommendations by the Consortium for Spinal Cord Medicine, 7 cervical and upper thoracic cord injuries down to T6 warrant a Dobutamine exerts its effect prominently as an inotropic agent and its use in SCI is limited because of its effect on vasodilation and possible reflex bradycardia. 24 Epinephrine, even though it is both an a-receptor and b-receptor agonist, may cause arrhythmias and require close monitoring.
Vasopressin is not used in the setting of SCI because of its antidiuretic effects leading to water retention and hyponatremia. 17 It is only used in cases of hypotension refractory to catecholamines. 23 Isoproterenol, amiodarone and milrinone cannot reverse hypotension in SCI. 23 In SCIs, the choice of the appropriate vasopressor depends on the patient's hemodynamic profile and the level of the cord injury and usually is an agent containing mainly a 1 -adrenergic activity but also sometimes b 1 -adrenergic activity.
Neurogenic shock starts immediately after injury when the spinal sympathetic pathways are disconnected at the site of injury while parasympathetic discharge continues unopposed through the vagal nerve. This may last for several days to 6 weeks until segmental neuronal connections and reflex cycles gradually reappear distal to the level of injury, even without sympathetic discharge return. 25 At that time, reflex hyperactivity begins manifesting as muscle spasms and elevation of blood pressure. 14, 26 Furthermore, Ko and coworkers 27, 28 specified that the time of return of deep tendon reflexes after SCI is within the first couple of weeks after injury with the delayed plantar reflex being the first followed by the bulbocavernous and cremasteric reflex. However, no established connection between spinal shock and neurogenic shock does exist. Vale et al. used a minimum duration of 7 days after injury for hemodynamic treatment of symptomatic patients. 6, 16 This duration was determined based on an experimental animal SCI study that showed that between days 3 and 5 after injury, the spinal cord experienced the greatest degree of cord edema and vascular congestion. 29 Levi et al. 5 used dobutamine at a mean dose of 5.4 mg kg À1 per min for a mean duration of 5.7 days. Our study found that most clinicians performed vasopressor support for approximately 5-7 days. Longer duration of treatment may interfere with renal function due to the adrenergic effect on the renal arteries.
Mean arterial pressure is determined by arterial catheter placement. It can be determined by the formula MAP ¼ DAP þ 1/3(SBPÀDBP), where DAP stands for diastolic blood pressure and SBP for systolic blood pressure. 23 Maintaining MAP above 85-90 mm Hg has been shown to improve the outcome of patients with ASCI.
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should not be elevated above the normal range even in severe cord injuries, as experimental studies have shown. 12 The goal of treating hypotension in patients with SCI should be to maintain an SBP at or above 85-90 mm Hg, according to consensus panel of Consortium for Spinal Cord Medicine. 7 
Conclusions
Given that rectifying systemic hypotension is one of the only clinical interventions that currently appear to influence neurologic outcome after ASCI, it is surprising that so little clinical evidence exists to address the fundamental questions that we posed in this systematic review. This relates to the problems that have plagued the SCI field in evaluating interventions that potentially alter neurologic outcome: the relatively low incidence of ASCI (making patient recruitment into clinical trials difficult), and the strikingly variable extent of spontaneous neurologic recovery among individuals of different ASIA impairment grades (making it necessary to recruit many patients to have sufficient statistical power). 
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